<DOC>
	<DOCNO>NCT02015676</DOCNO>
	<brief_summary>This study define optimal chemotherapy dose regimen Myocet combination paclitaxel intravenous Herceptin evaluate efficacy safety dose regimen patient metastatic locally advanced breast cancer HER2 overexpression . The anticipated time study treatment 3-12 month .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Combination Chemotherapy Patients With Metastatic Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>woman 1870 year age ; metastatic locally advanced breast cancer ; HER2 overexpression ; &gt; = 1 measurable lesion . prior treatment advance breast cancer ; prior treatment Herceptin ; bone central nervous system metastasis site disease ; history another malignancy ( except basal cell skin cancer cancer situ uterine cervix , contralateral breast cancer ) within 5 year study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>